502 related articles for article (PubMed ID: 23750791)
1. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
Reardon DA; Wucherpfennig KW; Freeman G; Wu CJ; Chiocca EA; Wen PY; Curry WT; Mitchell DA; Fecci PE; Sampson JH; Dranoff G
Expert Rev Vaccines; 2013 Jun; 12(6):597-615. PubMed ID: 23750791
[TBL] [Abstract][Full Text] [Related]
2. Recent advances and future of immunotherapy for glioblastoma.
Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy advances for glioblastoma.
Reardon DA; Freeman G; Wu C; Chiocca EA; Wucherpfennig KW; Wen PY; Fritsch EF; Curry WT; Sampson JH; Dranoff G
Neuro Oncol; 2014 Nov; 16(11):1441-58. PubMed ID: 25190673
[TBL] [Abstract][Full Text] [Related]
4. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation for glioblastoma.
Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma antigen discovery--foundations for immunotherapy.
Azad TD; Razavi SM; Jin B; Lee K; Li G
J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
8. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
10. DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE.
Glavatskyi O; Khranovska N; Skachkova O; Gorbach O; Khmelnytskyi H; Shuba I; Pedachenko Y; Zemskova O; Zemskova O
Exp Oncol; 2023 Dec; 45(3):282-296. PubMed ID: 38186026
[TBL] [Abstract][Full Text] [Related]
11. Using viral vectors to deliver local immunotherapy to glioblastoma.
Haddad AF; Young JS; Aghi MK
Neurosurg Focus; 2021 Feb; 50(2):E4. PubMed ID: 33524947
[TBL] [Abstract][Full Text] [Related]
12. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
13. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
14. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
16. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
Majd N; de Groot J
Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
[No Abstract] [Full Text] [Related]
17. The progress of immunotherapy for glioblastoma.
Zhou Q; Wang Y; Ma W
Hum Vaccin Immunother; 2015; 11(11):2654-8. PubMed ID: 26308501
[TBL] [Abstract][Full Text] [Related]
18. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
19. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.
Schijns VE; Pretto C; Devillers L; Pierre D; Hofman FM; Chen TC; Mespouille P; Hantos P; Glorieux P; Bota DA; Stathopoulos A
Vaccine; 2015 May; 33(23):2690-6. PubMed ID: 25865468
[TBL] [Abstract][Full Text] [Related]
20. Current challenges in designing GBM trials for immunotherapy.
Weathers SP; Gilbert MR
J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
